Research programme: anti-phosphatidylserine monoclonal antibodies - Affitech/Peregrine Pharmaceuticals

Drug Profile

Research programme: anti-phosphatidylserine monoclonal antibodies - Affitech/Peregrine Pharmaceuticals

Alternative Names: 11.31; 1N11; 3J05; AT 004; AT 005; Fully human bavituximab; PGN 632; PGN 634; PGN 635

Latest Information Update: 15 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Affitech A/S; Peregrine Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Phosphatidylserine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Cancer
  • Research HIV infections; Lassa fever; Viral haemorrhagic fevers; Viral infections; Yersinia infections

Most Recent Events

  • 19 Sep 2014 Development in Cancer and Infections is ongoing
  • 20 Apr 2010 Immunogenicity data from a preclinical trial in Cancer presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
  • 05 Apr 2010 Early research in HIV infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top